Stockscreener 앱 받기
2.68
3.08%
0.08
시장 영업 전:
2.71
0.03
+1.12%
Editas Medicine Inc 주식(EDIT)의 최신 뉴스
EDIT|Editas Medicine Inc|Price:2.680|Chg%:+0.080 - TradingKey
Editas Medicine Inc (EDIT) Cash Flow - TradingKey
Editas Medicine Inc (EDIT) Income Statement - TradingKey
Editas Medicine Inc (EDIT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Editas Medicine Inc (EDIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Editas Medicine, Inc. Revenue Breakdown – NASDAQ:EDIT - TradingView
Editas Medicine Inc (EDIT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Editas Medicine Slips 2.34% as Gene Editing Stock Tests Key Support at $2.57Fear Greed Extreme - dars.gov.et
Form 144 Editas Medicine For: 22 July By Investing.com - Investing.com Nigeria
Editas Medicine stock trades steady as gene-editing pipeline advances and cash runway extends - Ad-hoc-news.de
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Editas Medicine (EDIT) insider plans to sell 5,500 shares after RSU vesting - Stock Titan
Editas Medicine (EDIT) 10K Form and Latest SEC Filings 2026 - MarketBeat
Editas Medicine stock steadies as gene-editing pipeline advances after Q1 loss narrows - Ad-hoc-news.de
Editas Medicine (NASDAQ:EDIT) Share Price Passes Below Fifty Day Moving AverageWhat's Next? - MarketBeat
Lyora Therapeutics Launches With Seed Funding to Propel Its Biologically Validated Pipeline of Genetic Medicines to Treat Inherited Retinal Diseases - GlobeNewswire Inc.
Exclusive: Genetic medicine startup launches to speed programs that stalled at Editas, Biogen - Endpoints News
Editas Medicine (EDIT) Slips 1.21%, Tests Support Near $3.10 Amid Gene-Editing Sector PressurePullback Trade - dars.gov.et
What pharma leaders wish they knew on day 1 - Pharma Voice
Editas Medicine Slips Slightly, Holds Above Key Support LevelHigh Yield Stocks - DonanımHaber
Editas Medicine appoints PwC as new auditor, dismisses Ernst & Young - Investing.com
Editas Medicine stock holds the line as pipeline work continues. - Ad Hoc News
Editas Medicine Surges 11% on Strong Volume, Testing Key Resistance at $3.83Long Short Pair - dars.gov.et
EDIT's Q1 loss narrower than expected, pipeline in focus - MSN
Editas Medicine, Inc.(NasdaqGS:EDIT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 2500 Growth Benchmark - marketscreener.com
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 2000 Growth Benchmark - marketscreener.com
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 3000E Growth Benchmark - marketscreener.com
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Price to sales forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
Price to sales forward of Editas Medicine, Inc. – LSE:0IFK - TradingView
Price to earnings forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
Enterprise value to EBITDA forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
Price to earnings forward of Editas Medicine, Inc. – LSE:0IFK - TradingView
Enterprise value to revenue forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
EDIT Q1 2026 Earnings: Narrowing Losses Amid Pipeline ProgressMid-Term Outlook - dars.gov.et
Price to book forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
Editas Medicine, Inc. Actuals & Estimates (NASDAQ:EDIT) - TradingView
Enterprise value to EBITDA forward of Editas Medicine, Inc. – LSE:0IFK - TradingView
Editas Medicine, Inc. Actuals & Estimates (LSE:0IFK) - TradingView
EDIT Forecast — Price Target — Prediction for 2027 - TradingView
Editas Medicine, Inc. Actuals & Estimates (FWB:8EM) - TradingView
Editas Medicine Inc (EDIT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Editas Medicine, Inc. Actuals & Estimates (BOATS:EDIT) - TradingView
8EM Forecast — Price Target — Prediction for 2027 - TradingView
Editas Medicine Inc (EDIT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Hirsch Andrew - Moomoo
Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Scadden David - Moomoo
Editas Medicine Inc (EDIT) Institutional Confidence - TradingKey
Form 4 Editas Medicine For: 22 June By Investing.com - Investing.com South Africa
[Form 4] Editas Medicine, Inc. Insider Trading Activity - Stock Titan
Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Connaughton Bernadette - Moomoo
Editas Medicine (NASDAQ: EDIT) director granted 51,700 stock options at $2.55 - Stock Titan
Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Hopfield Jessica - Moomoo
Editas Medicine (EDIT) director Andrew Hirsch awarded 51,700 stock options - Stock Titan
Editas Medicine (EDIT) director awarded 51,700 stock options at $2.55 strike - Stock Titan
Editas Medicine (EDIT) director granted 51,700 stock options at $2.55 strike - Stock Titan
1.97%
0.83%
자본화:
|
볼륨(24시간):